Page 1 of 2
12

2024 (2 POSTS)

Kougias DG, Killius A, Collins J, Russman E, Maddaloni M. 2024. Per- and polyfluoroalkyl substances (PFAS) in drinking water: A retrospective case series with risk assessments. Chapter 7 in: Paustenbach DJ (ed), Human and Ecological Risk Assessment: Theory and Practice, Third Edition. Wiley, ISBN: 978-1-119-74296-8, pp. 337–396.

Racz L, Gauthier A, Bare J, Heintz M, Feifarek D, Kennedy S, Panko J. 2024. Assessment of perfluorocarboxylic acids in fluorinated high-density polyethylene containers and estimation of potential non-cancer risks associated with anticipated use scenarios. Regul Toxicol Pharmacol 147:105560; doi: 10.1016/j.yrtph.2024.105560.

View Abstract

2022 (3 POSTS)

Heintz MM, Chappell GA, Thompson CM, Haws LC. 2022. Evaluation of transcriptomic responses in livers of mice exposed to the short-chain PFAS compound HFPO-DA. Front Toxicol 4:937168, https://doi.org/10.3389/ftox.2022.937168.

View Abstract

Lea IA, Pham LL, Antonijevic T, Thompson C, Borghoff SJ. 2022. Assessment of the applicability of the threshold of toxicological concern for per- and polyfluoroalkyl substances. Regul Toxicol Pharmacol 133:105190, open access.

View Abstract

Racz L. PFAS: How did we get here and where are we going? Keynote address at Alliance of Hazardous Materials Professionals national meeting, Las Vegas, NV, March 2022.

View Abstract

2021 (1 POST)

Kempisty DM, Racz L. 2021 (in press). Forever Chemicals: Environmental, Economic, and Social Equity Concerns with PFAS in the Environment. Routledge, Taylor and Francis Group, ISBN 9780367456405.

View Abstract

2020 (4 POSTS)

Chappell GA, Thompson CM, Wolf JC, Cullen JM, Klaunig JE, Haws LC. 2020. Assessment of the mode of action underlying the effects of GenX in mouse liver and implications for assessing human health risks. Toxicol Pathol 48(3):494–508, doi: 10.1177/0192623320905803. PMID: 32138627.

View Abstract

Haws L (session co-chair). Introduction to “Use of New Approach Methods in Risk Characterization of PFAS: Challenges and Opportunities.” 44th Annual Winter Meeting, the Toxicology Forum, Tysons, VA, Jan 2020 (see: https://dialogue.toxforum.org/d/do/894).

Thompson CM, Ring C, Pham L, Chappell GA, Haws LC. Assessment of the relevance of toxicological findings in the development of an oral reference dose for GenX. Poster for Society of Toxicology, Virtual Annual Meeting, 2020.

View Abstract

Pham LL, Borghoff SJ, Thompson CM. 2020. Comparison of threshold of toxicological concern (TTC) values to oral reference dose (RfD) values. Regul Toxicol Pharmacol 113:104651 [open access].

View Abstract

2019 (6 POSTS)

Thompson C, Chappell G, Cullen J, Wolf JC, Haws L. Development of an oral reference dose for GenX using the latest toxicological and risk assessment methodologies: Environmental risk assessment of per- and polyfluoroalkyl substances (PFAS). SETAC North America Focused Topic Meeting, Durham, NC, August 2019.

Chappell GA, Thompson CM, Wolf J, Cullen J, Haws LC. Transcriptomic responses in livers of GenX-treated mice demonstrate up-regulation of PPAR signaling and related pathways. Environmental Mutagenesis and Genomics Society, Washington, DC, September 2019.

Thompson CM. The useful chemistry of perfluorinated compounds: Managing safety. The sticky subject of non-stick: Regulatory science challenges of per- and poly-fluorinated compounds (PFAS). Texas A&M University Interdisciplinary Faculty of Toxicology Training Program, 2019 Annual Regulatory Science Symposium. August 20, 2019.

Thompson CM, Fitch SE, Ring C, Rish W, Cullen JM, Haws LC. 2019. Development of an oral reference dose for the perfluorinated compound GenX. J Appl Toxicol 39:1267–1282.

View Abstract

Ring CL, Rish WR, Brorby GL. Prioritization of eight PFAS by population exposure and reference-dose uncertainty. Poster session at SETAC North America Focused Topic Meeting “Environmental Risk Assessment of PFAS”, Durham, NC, August 2019.

Borghoff SJ, Fitch S, Huggett, Wikoff D. A hypothesis-driven weight-of-evidence analysis to evaluate potential endocrine disrupting properties of perfluorohexanoic acid (PFHxA). 2019. Poster at Society of Toxicology Annual Meeting, Baltimore, MD, March 2019.

View Abstract

2018 (3 POSTS)

Borghoff SJ, Fitch S, Rager JE, Huggett D. 2018. A hypothesis-driven weight-of-evidence analysis to evaluate potential endocrine activity of perfluorohexanoic acid. Regul Toxicol Pharmacol 99:168–181.

View Abstract

Kempisty DM, Xing Y, Racz L (eds). 2018. Perfluoroalkyl Substances in the Environment: Theory, Practice and Innovation. Taylor and Francis CRC Press: Boca Raton, FL.

View Abstract

Thompson CT, Suh M, Chappell G, Borghoff S, Ellis-Hutchings, R, Wiench, K, Finch, L, Proctor, DM. 2018. Assessment of the mode of action underlying development of forestomach tumors in rodents following oral exposure to ethyl acrylate and relevance to humans. Regul Toxicol Pharmacol 96:178–189 doi: 10.1016/j.yrtph.2018.05.006.

2007 (1 POST)

Paustenbach DJ, Panko JM, Scott PK, Unice KM. 2007. A methodology for estimating human exposure to perfluorooctanoic acid (PFOA): A retrospective exposure assessment of a community (1951-2003). J Toxicol Environ Health A 70(1):28–57.

View Abstract
Page 1 of 2
12